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ABSTRACT
EMMPRIN/CD147 is mainly known for its protease inducing function but a role 
in promoting tumor angiogenesis has also been demonstrated. This study provides 
evidence that EMMPRIN is a new coreceptor for the VEGFR-2 tyrosine kinase receptor 
in both endothelial and tumor cells, as it directly interacts with it and regulates its 
activation by its VEGF ligand, signalling and functional consequences both in vitro 
and in vivo. Computational docking analyses and mutagenesis studies identified a 
molecular binding site in the extracellular domain of EMMPRIN located close to the 
cell membrane and containing the amino acids 195/199. EMMPRIN is overexpressed 
in cancer and hence is able to further potentiate VEGFR-2 activation, suggesting 
that a combinatory therapy of an antiangiogenic drug together with an inhibitor of 
EMMPRIN/VEGFR-2 interaction may have a greater impact on inhibiting angiogenesis 
and malignancy.
INTRODUCTION
Angiogenesis is a key component of the tumor 
microenvironment, essential for tumor growth and invasion. 
Among the angiogenic regulators, vascular endothelial 
growth factor (VEGF) is known to be the major actor not 
only in endothelial cells but also in tumor cells, promoting 
survival, proliferation, apoptosis and migration [1].
VEGF exerts its angiogenic effects by binding to its 
main receptor (VEGFR-2) or KDR [1, 2]. Binding initiates 
receptor dimerization which subsequently activates the 
intracellular tyrosine kinase domains [2]. Active VEGFR-2 
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then initiates several downstream cell signalling pathways, 
including stress-activated protein kinase 2/p38 MAP 
kinase, phosphatidylinositol-f3 kinase, Focal Adhesion 
Kinase (FAK) and AKT, which culminate in endothelial 
cell migration, proliferation and vessel formation. 
The extracellular domain of VEGFR-2 consists of 7 Ig-
homology domains. The first 3 domains were shown to 
mediate ligand binding whereas the membrane proximal 
domains are involved in ligand-induced receptor 
dimerization [3–5].
EMMPRIN/CD147, a membrane spanning gly-
coprotein particularly known as a regulator of matrix 
degrading proteinases such as MMPs and uPA, has 
been more recently shown by us and by others [6–8] 
to be implicated in angiogenesis via the regulation of 
VEGF expression. Our more recent reports described the 
concomitant regulation by EMMPRIN of VEGF receptor 
VEGFR-2 in both endothelial cells and tumor cells, in a 
mechanism mediated by HIF-2 alpha [9] thus increasing 
respectively angiogenesis and malignancy. It was also 
shown to have several other malignancy promoting 
functions including tumor cell invasion, survival and 
anchorage-independent growth [10]. Indeed, EMMPRIN 
has been greatly implicated in malignancy as it is highly 
expressed in most cancer tissues and its expression often 
correlates with tumor progression [11–14].
EMMPRIN belongs to the immunoglobulin (Ig) 
superfamily and is composed of two C2-like immu-
noglobulin extracellular domains, a transmembrane 
domain and a short cytoplasmic domain [15]. The 
extracellular region, which contains three conserved 
N-glycosylation sites that are variably glycosylated, has 
been implicated in EMMPRIN self association [16], 
while the first Ig domain within this region is required 
for counter-receptor activity involved in MMP induction 
[17]. The highly conserved transmembrane domain and 
the short cytoplasmic domain are thought to be implicated 
in interactions between EMMPRIN and other molecular 
partners within the membrane. In particular, EMMPRIN 
was shown to interact with integrins α3β1 and α6β1, 
enhancing the adhesion and spreading of the cell to the 
ECM [18] and to caveolin-1 in lipid rafts leading to a 
decrease in EMMPRIN cell surface self association [19]. 
The ability of EMMPRIN to associate with different 
proteins was suggested to determine the different cellular 
functions attributed to it, although the nature of such 
interactions and their involvement in signal transduction 
has not yet been determined.
Our present study uncovered, in both endothelial 
cells and tumor cells, a unique mechanism of action 
showing that a direct interaction of EMMPRIN with 
VEGFR-2 on the plasma membrane is required for VEGF-
induced VEGFR-2 activation and downstream signaling. 
These findings have to be taken in account in tumor 
angiogenesis combinatorial therapy development.
RESULTS
EMMPRIN/CD147 interacts with VEGFR-2 
in its non-phosphorylated and phosphorylated 
forms in endothelial and tumor cells in vitro 
and in vivo
The potential interaction between EMMPRIN and 
VEGFR-2 was investigated by immunoprecipitation 
(IP) assays in endothelial cells HMEC and melanoma 
cells M10. Complex formation was identified by the 
immunoprecipitation of either VEGFR-2 or VEGF 
followed by EMMPRIN immunoblotting (Figure 1A). 
IgG was used as a negative control. The fluorescent red 
spots observed using in situ proximity ligation assay 
(PLA) (Figure 1B) and confocal microscopy, a method 
which highlights protein/protein closely colocalized in 
cells, confirmed the proximity between EMMPRIN and 
VEGFR-2, and to a lesser extent between EMMPRIN and 
VEGF, at the cell surface.
To further investigate whether EMMPRIN interacts 
directly with VEGFR-2 in a cell-free system, we performed 
pull-down assays using recombinant EMMPRIN and 
recombinant VEGFR-2. Our results show that VEGFR-2 
bound specifically to EMMPRIN and to the same extend as 
to VEGF, used as a positive control (Figure 1C).
The specificity of EMMPRIN/VEGFR-2 inter action 
was demonstrated by the decrease in the imm unoprecipitated 
(IP) complex when EMMPRIN expression was silenced 
using siRNA strategy (Figure 1D). This was confirmed by 
PLA assay showing a large decrease in the number of red 
dots of cells transfected with EMMPRIN siRNA in both 
endothelial and tumor cells compared with its corresponding 
scrambled siRNA (Figure 2). Similar results were obtained 
with BLM melanoma cells (not shown).
We have next shown that EMMPRIN also interacted 
with the active form of VEGFR-2 and this interaction was 
enhanced after VEGF treatment of endothelial as well as 
melanoma cells. EMMPRIN/pVEGFR-2 heterodimers 
are visualized by PLA red dots in Figure 3A. Importantly, 
intense clustering pattern of these EMMPRIN/pVEGFR-2 
heterocomplexes were also observed in human breast 
cancer (n = 11) and melanoma (n = 15) tissues (Figure 3B) 
demonstrating the implication of EMMPRIN/pVEGFR-2 
interactions in vivo.
To investigate the role of EMMPRIN in VEGF/
pVEGFR-2 interaction in vivo, we generated melanoma 
BLM cells with stable knockdown of EMMPRIN 
(EMMPRIN-miRNA) for injection in nude mice. The 4 
clones of BLM-EMMPRIN-miRNA analyzed showed a 
decrease in EMMPRIN expression (protein and mRNA) 
in comparison to BLM-srambled-miRNA. This decrease 
was greatest in clone 2 and 4 which also correlated with 
the lowest invasive capacity of these clones; clone 4 was 
chosen for the in vivo studies (Figure 4A, 4B, 4C).
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Analysis of tumor xenograft sections showed a 
decrease in pVEGFR-2 immunostaining and in EMMPRIN/
pVEGFR-2 interaction in EMMPRIN knockdown tumors 
(BLM-EMMPRIN-miRNA), compared to control tumors 
(BLM-scrambled-miRNA). Importantly, this was associated 
with a significant decrease in VEGF/pVEGFR-2 interaction 
(Figure 4D, 4E).
EMMPRIN is required for VEGF-mediated 
VEGFR-2 activation and downstream signalling
We next investigated the potential role of 
EMMPRIN in the activation of VEGFR-2 by its VEGF 
ligand. Immunoprecipitation of VEGFR-2 followed 
by immunoblotting with pVEGFR-2 antibody have 
shown that EMMPRIN knockdown by siRNA decreased 
VEGFR-2 phosphorylation mediated by VEGF, in both 
endothelial and tumor cells (Figure 5A). Furthermore, 
PLA experiments have shown that the reduced activation 
of VEGFR-2 observed with EMMPRIN inhibition was 
associated with a decrease in both VEGF/pVEGFR-2 
interaction (Figure 5B) and VEGFR-2 homodimerization 
(Figure 5C) (the decrease was even greater in the presence 
of VEGF), demonstrating the importance of EMMPRIN 
in VEGFR-2 phosphorylation mediated by VEGF 
(Figure 5B). Phospho-Proteome Profiler Array analysis 
showed that certain VEGF-induced downstream signals 
were inhibited upon EMMPRIN silencing (Figure 5D). Of 
interest, the activation of p38 and its downstream HSP27 
involved in migration were impaired, but not that of the 
Figure 1: EMMPRIN/CD147 interacts with VEGFR-2 and VEGF in endothelial and tumor cells. (A) VEGFR-2 and 
VEGF from HMEC and M10 cell lysates were immunoprecipitated (IP) with anti-VEGFR-2 and anti-VEGF antibody respectively; 
western blotting was performed using anti-EMMPRIN antibody. Non immune IgG was used as controls. Representative blots of three 
independent experiments are shown. (B) In situ Proximity ligation assay (PLA) detection of EMMPRIN-VEGFR-2 and EMMPRIN-VEGF 
heterodimers (red dots). Negative controls without primary antibody are also shown. Nuclei were stained with DAPI (blue), magnification 
x 63. Representative images of three independent experiments are shown. (C) Direct interaction between the recombinant EMMPRIN and 
the recombinant VEGFR-2 in vitro. VEGFR-2 was first incubated with protein G beads prior to the addition of the recombinant EMMPRIN. 
Bound proteins were subsequently analyzed by Western blotting. Non-immune IgG served as a negative control and interaction between 
VEGF and VEGFR-2 served as a positive control. (D) Cells (HMEC, MDA-MB-231 and M10) were transfected for 24 hours with EMMPRIN 
siRNA or scrambled control siRNA at 33nmol/L concentration, and then subjected to IP assays using antibodies against VEGFR-2 and 
VEGF. Western blotting was performed using anti-EMMPRIN antibody. Representative blots of three independent experiments are shown.
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kinases FAK or Src. In addition, the PLCγ-1/MEK1/2 
pathway involved in cell proliferation was also affected. 
These findings suggest a role of EMMPRIN in VEGF 
signalling.
The functional consequence of this regulation was 
demonstrated by a decrease in cell migration observed in 
EMMPRIN siRNA transfected cells that was not restored 
after VEGF treatment.
Cell migration was investigated using modified 
Boyden chamber assays. Migration of HMEC, M10 and 
MDA-MB-231 cells in which EMMPRIN was inhibited 
with siRNA was measured in the presence or not of VEGF. 
As shown in Figure 6, EMMPRIN silencing greatly 
inhibited cell migration stimulated by VEGF in the studied 
models.
A molecular model for EMMPRIN/VEGFR-2 
direct interaction
The above findings indicate that EMMPRIN 
interacts with VEGFR-2 to enhance its activation by 
VEGF, therefore we aimed to build a structural model 
for EMMPRIN/VEGFR-2 complex that could explain 
the experimental results. Modeling this system presented 
several major challenges such as: (i) it was not known 
whether EMMPRIN interacts with VEGFR-2 as monomer, 
dimer or oligomer; (ii) the interacting molecules are 
expected to have significant interdomain flexibility; and 
(iii) it was not known which VEGFR-2 domain could be 
involved in the interaction. Therefore we performed a 
comprehensive modeling strategy using all the available 
structural information for the possible interacting domains 
(see Methods). The best docking model was obtained by 
using one of the EMMPRIN monomers from the x-ray 
structure and a two-domain construct of VEGFR-2 D6-D7 
domains. Interestingly, the lowest-energy binding mode 
obtained by docking simulations was compatible with 
membrane binding, and had the majority of interactions 
between EMMPRIN D2 and VEGFR-2 D6 domains 
(Figure 7).
Site-directed mutagenesis confirm EMMPRIN/
VEGFR-2 interaction model
The contribution of hot spots residues to EMMPRIN/
VEGFR-2 interaction according to the above described 
model was examined by computational analysis. The 
EMMPRIN/VEGFR-2 interface according to this model is 
highly electrostatic (Figure 7B). Based on the model, and 
considering the residues with highest electrostatic binding 
energy that were not involved in important intra-domain 
interactions, the following EMMPRIN mutants were 
constructed in order to validate the binding interface site: 
D144A, Q182A, R184A, Q195A, T199A (Figure 7). We 
also generated Q182A/R184A and Q195A/T199A double 
mutants (see Methods). D136A was defined as a negative 
control, since according to the model this residue should 
not be involved in the interaction.
We first transfected BLM-EMMPRIN-miRNA 
cells with EMMPRIN full length cDNA (wide type: WT) 
Figure 2: EMMPRIN silencing decreases EMMPRIN/VEGFR-2 interaction in endothelial and tumor cells. Cells were 
transfected with EMMPRIN siRNA or scrambled siRNA prior to in situ PLA for EMMPRIN-VEGFR-2 interaction. Cell nuclei were 
stained with DAPI (blue), magnification x 63. The detected dimers (EMMPRIN/VEGFR-2) are represented as red dots. Representative 
images of three independent experiments are shown. Quantification of PLA signals was performed on ~150 transfected cells per condition 
in three independent experiments; mean PLA signal/cell ± SD are plotted. ***P ≤ 0.0001.
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or mutated on the following residues: D136A, D144A, 
Q182A, R184A, Q195A, T199A, Q182A/R184A and 
Q195A/T199A. EMMPRIN/VEGFR-2 binding was eval-
uated by immunoprecipitation using an antibody directed 
against VEGFR-2 (Figure 8). Results show that both 
the single and the double mutants reduced EMMPRIN/
VEGFR-2 binding to a varying degrees but the greatest 
reduction was observed with the double mutant Q195A/
T199A pointing to the importance of this site in the 
interaction. By contrast, the negative control D136A mutant 
had no detectable effect on EMMPRIN/VEGFR-2 binding.
The role of these EMMPRIN residues on the 
activation of VEGFR-2 by its ligand VEGF was inves-
tigated by studying the binding behaviour of the 
EMMPRIN mutants towards VEGF-induced VEGFR-2 
activation. Figure 9 shows a total inhibition of pVEGFR-2 
activation by VEGF with the double mutant Q195A/
T199A while the other single mutants had lower effects 
(Figure S1). This is consistent with the VEGF/pVEGFR-2 
interaction results obtained by in situ PLA.
Altogether, our results uncovered a novel 
mechanism by which EMMPRIN regulates VEGFR-2 
activation by direct binding, modulating its downstream 
signalling and functional consequences.
DISCUSSION
EMMPRIN/CD147 has been reported to play 
crucial roles not only in matrix proteolysis and tumor 
invasion but also in angiogenesis [8]. We hypothesized 
Figure 3: EMMPRIN interacts with pVEGFR-2 in vitro and in vivo. (A) EMMPRIN interacts with pVEGFR-2 in HMEC 
endothelial cells and M10 tumor cells. In situ PLA for EMMPRIN/pVEGFR-2 was performed after VEGF stimulation (5 minutes, 50 
ng/ml); red dots represent EMMPRIN-pVEGFR-2 interaction; nuclei are stained with DAPI (blue). Representative images of three 
independent experiments are shown. Quantification of PLA signals was performed on ~150 transfected cells per condition in three 
independent experiments; mean PLA signal/cell ± SD are plotted. **P ≤ 0.001. (B) EMMPRIN interacts with pVEGFR-2 in human cancer 
tissues. In situ PLA detection of EMMPRIN and pVEGFR-2 interaction in human melanoma tissues (M202 and M165) and in human breast 
cancer tissues (B132 and B18) using antibodies against EMMPRIN and pVEGFR-2. Nuclei were stained with DAPI (blue); phase contrast 
indicates cell contour (grey); the panels show high magnification (x 40) to clearly visualize the PLA spots representing heterodimers. 
Representative photos of three independent experiments are shown.
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that a possible link between EMMPRIN and VEGFR-2 
may exist since both these membrane receptors localized 
on endothelial and tumor cell surface are involved in 
common functional properties, notably angiogenesis. In 
this study, we uncovered a novel function of EMMPRIN 
as a coreceptor of VEGFR-2, as it directly interacts with 
it and regulates its activation, signalling and functional 
consequences. Furthermore, in both endothelial and tumor 
cells, EMMPRIN enhanced VEGF-induced VEGFR-2 
phosphorylation, downstream signalling of the VEGF-
induced pathway, and consequently cell migration. Our 
results show that EMMPRIN/VEGFR-2 interaction 
involves a binding site located in the extracellular domain 
of EMMPRIN which contains the amino acids 195/199 
located very close to the cell membrane, since mutating 
this site blocked the interaction. In addition, our in vivo 
studies showed that VEGF/pVEGFR-2 interaction is 
significantly impaired in mice injected with EMMPRIN-
miRNA transfected BLM.
It is interesting to note that high expression of 
EMMPRIN in human renal cancer was reported to be 
involved in sunitinib (VEGFR inhibitor) resistance [20]. 
Figure 4: EMMPRIN knockdown decreases EMMPRIN/pVEGFR-2 and VEGF/pVEGFR-2 interactions 
in vivo. Melanoma cell line BLM was transfected with EMMPRIN-miRNA (BLM-EMMPRIN-miRNA) or scrambled-miRNA (BLM-
Scrambled-miRNA).EMMPRIN expression in 4 different clones was analyzed by: (A) western blot (Western Blot was performed 
usinganti-EMMPRIN antibody normalized to actin; representative blots of three independent experiments); (B) by qRT-PCR (means 
of relative expression to the reference gene PPIA of at least 3 independent experiments, error bars refer to 95% confidence intervals;  
*P < (0.05)) and (C) Invasion assay using a modified Boyden chamber was performed with clone 4 BLM-EMMPRIN-miRNA. 
Representative images of three independent experiments are shown. EMMPRIN/pVEGFR-2 interaction in experimental mouse model 
using EMMPRIN deficient tumor cells. Melanoma cell line BLM was transfected with EMMPRIN-miRNA (BLM-EMMPRIN-miRNA) 
or scrambled-miRNA (BLM-Scrambled-miRNA). (D) Immunofluorescence analysis of pVEGFR-2 in xenograft tumors from Scrambled-
miRNA or EMMPRIN-miRNA BLM cells 5 weeks after injection. Representative images of 10 primary tumors analysed are shown. 
(E) EMMPRIN/pVEGFR-2 and VEGF/pVEGFR-2 interactions in EMMPRIN-silenced xenografts by in situ PLA. Nuclei were stained 
with DAPI (blue), magnification x 40. Representative images of 10 primary tumors analysed are shown. Quantification of PLA signals 
was performed on ~150 transfected cells per condition in three independent experiments; mean PLA signal/cell ± SD are plotted.  
**P ≤ 0.001;***P ≤ 0.0001.
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As EMMPRIN is highly expressed in cancer its interaction 
with VEGFR-2 may represent one underlying mechanism 
of this resistance.
In order to determine whether EMMPRIN/VEGFR-2 
binding could explain the enhancement in VEGF-mediated 
VEGFR-2 dimer formation and VEGFR-2 activation by 
EMMPRIN, we explored the possible oligomerization 
state of EMMPRIN when interacting with VEGFR-2 
in our model. It has been reported that EMMPRIN can 
dimerize in cis (both monomers in the membrane of the 
same cell), through the domain D1, but the structure 
of the dimer is not known. Therefore, we modeled the 
dimer of EMMPRIN extracellular domains by docking 
two monomers from the x-ray structure (see Methods). 
Interestingly, the lowest-energy docking solution is 
symmetric and would be compatible with membrane 
attachment (Figure 10). It should be noted that it was 
impossible to find a dimer conformation that fully satisfied 
the recently reported mutational data on EMMPRIN 
dimerization in solution, which suggests that membrane 
attachment imposes additional structural restraints to 
EMMPRIN dimerization [21].
We combined the above described models obtained 
for EMMPRIN/VEGFR-2 complex and EMMPRIN dimer, 
allowing interdomain flexibility with NMA (see Methods), 
and found many possible rearrangements that are 
compatible with membrane attachment (see an example 
in Figure 11A). Interestingly, with a small interdomain 
Figure 5: EMMPRIN enhances VEGF-mediated VEGFR-2 activation (phosphorylation and homodimerization) 
in EMMPRIN silenced HMEC and M10 cells. Phosphorylation of VEGFR-2 by VEGF (5 minutes, 50 ng/ml) was assessed 
by: (A) VEGFR-2 IP followed by immunoblotting for pVEGFR-2 and VEGFR-2 used as loading control (representative blots of 
three independent experiments are shown), and (B) In situ PLA showing VEGF/pVEGFR-2 interaction (red dots).Quantification of 
PLA signals was performed on ~150 transfected cells per condition in three independent experiments; mean PLA signal/cell ± SD 
are plotted. ***P ≤ 0.0001 (magnification x 63). (C) In situ PLA detection of VEGFR-2 homodimers in HMEC endothelial cells. 
Nuclei were stained with DAPI (blue), magnification x 63. (D) VEGF-induced downstream signalling by Phospho-Proteome profiling 
of EMMPRIN silenced HMEC cells. Total cell lysates (300μg) were incubated with Human Phospho-Kinase Array membranes 
(containing 43 different kinases) (R&D systems) and developed by chemiluminescent system. Representative dots of selected kinases 
are shown.
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Figure 7: EMMPRIN/VEGFR-2 docking model. (A) Best-energy docking model for the interaction between EMMPRIN monomer 
(blue) and VEGFR-2 D6-D7 model (green). Interface residues are shown in ball & stick. (B) Surface representation of EMMPRIN monomer 
residues, colored according to their electrostatic contribution to the VEGFR-2 D6-D7 binding energy (highest contributors in red). Interface 
residues are highlighted.
Figure 6: EMMPRIN is required in VEGF-induced VEGFR-2 cell migration. Cell migration was determined using a transwell 
system. EMMPRIN siRNA transfected cells (HMEC, MDA-MB-231 and M10) were seeded in 24-well/insert of Boyden chambers and 
treated with VEGF (50 ng/ml). After 24 hours of incubation, cells were fixed, stained with Diff-Quick and counted under a microscope. 
Columns indicate means of 3 independent experiments carried out in triplicate; and bars, SD *P < 0.05.
rearrangement, the D7 domains could form a dimer as in 
VEGFR-2 D7 x-ray structure, keeping compatibility with 
membrane attachment (Figure 11B).
The model shown in Figure 7A for EMMPRIN/
VEGFR-2 interaction suggests that EMMPRIN can 
stabilize a VEGFR-2 dimer in which D7 domains are 
not in the expected proximity to activate VEGFR-2 
intracellular domain. This is compatible with our findings 
that EMMPRIN can dimerize VEGFR-2 (Figure 5C) 
but cannot activate it by itself (Figure 5A). However, 
we also found that EMMPRIN enhances VEGF-
mediated VEGFR-2 dimerization and thus activation 
of intracellular signalling (Figure 5A, 5C). A possible 
model for this is shown in Figure 11B. When EMMPRIN 
is present, it can help to recruit VEGFR-2 molecules and 
form dimers, so when VEGF is added, its probability 
of binding two VEGFR-2 monomers increases. The 
binding of VEGF to two VEGFR-2 monomers will 
facilitate the D7 domains to form a dimer so that the 
intracellular domains can adopt a suitable orientation that 
triggers auto-phosphorylation and thus activation of the 
intracellular signalling (Figure 11Ba). However, in the 
absence of EMMPRIN, unligated VEGFR-2 molecules 
are not necessarily located in the proximity of each other 
and therefore VEGFR-2 dimer formation after VEGF 
binding, although possible, would be a limiting step that 
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Figure 8: EMMPRIN amino acid residues 195–199 are required for EMMPRIN/pVEGFR-2 interaction. EMMPRIN/
VEGFR-2 interaction in BLM EMMPRIN-deficient cells transfected with EMMPRIN simple and double mutant constructs, control 
D136A and WT. After VEGFR-2 pull-downs, interaction with EMMPRIN was analyzed by Western blotting. Representative blots of 
three independent experiments are shown. In situ PLA using confocal microscopy shows red fluorescent spots which denote very close 
localization between EMMPRIN and pVEGFR-2. Fluorescence was markedly decreased with the double mutant Q195A/T199A. Nuclei 
were stained with DAPI (blue), magnification x 63. Representative images of three independent experiments are shown. Quantification 
of PLA signals was performed on ~150 transfected cells per condition in three independent experiments; mean PLA signal/cell ± SD are 
plotted.
could make the intracellular signalling activation less 
efficient (Figure 11Bb).
Taken together, these results provide evidence 
that EMMPRIN is a novel coreceptor of VEGFR-2. 
EMMPRIN plays a central role in its activation not 
only in angiogenesis but also in increasing tumor cells 
malignant properties mediated by VEGFR-2. This should 
have implications in the design of new strategies to inhibit 
VEGFR-2 activation. Several innovative antiangiogenic 
drugs have recently been developed. Doxazosin, an 
hypertension drug was shown to decrease VEGFR-2/
Akt/mTOR signalling and to exert antitumor effects in an 
animal model [22]. Beside such monotherapy approach, 
a combinatory strategy using, for example, a dual EGFR 
inhibition together with anti VEGF treatment have recently 
shown an improved clinical benefit [23]. In this context, 
our results propose a novel antiangiogenic approach using 
an inhibitor of EMMPRIN-VEGFR-2 interaction, which 
would be expected to be specific for tumor angiogenesis, 
as EMMPRIN is known to be highly expressed in cancer 
tissues. Its use in combination with an anti-angiogenic 




Human microvascular endothelial (HMEC) cells line 
derived from dermal microvasculature (T. Lawley, Emory 
University, Atlanta, GA) were maintained in MCDB-131 
medium (Gibco, Invitogen) with 10% fetal bovine serum 
(FBS) (Invitrogen), 2 ml glutamine (Invitrogen), 10ng/
ml endothelial growth factor (Upstate Biotechnology/
Millipore), and 1μg/ml hydrocortisone (Sigma-Aldrich). 
Primary melanoma M10 cells, established from patient 
primary nodular melanoma were maintained in RPMI 
medium (Gibco, Invitogen) with 10% FBS, Hepes 
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Figure 10: Scheme of the modeling procedure followed in this work. The final models were obtained by a combination of 
EMMPRIN (blue)/VEGFR-2 D6-D7 (green) docking, EMMPRIN/EMMPRIN docking and NMA-based conformational search. Those 
models compatible with the membrane attachement were selected.
Figure 9: EMMPRIN amino acid residues 195–199 are required for VEGF-mediated VEGFR-2 activation.  
VEGF-mediated VEGFR-2 phosphorylation in BLM EMMPRIN-deficient cells transfected with EMMPRIN double mutant constructs, 
control D136A and WT. VEGFR-2 phosphorylation by VEGF (5 min) was analyzed by VEGFR-2 IP followed by immunoblotting for 
pVEGFR-2 and VEGFR-2. Representative blots of three independent experiments are shown. In situ PLA was performed to identify 
VEGF/pVEGFR-2 interaction (red dots) with and without VEGF treatment. Nuclei are stained with DAPI (blue), magnification x 63. 
Representative images of three independent experiments are shown. Quantification of PLA signals was performed on ~150 transfected cells 
per condition in three independent experiments; mean PLA signal/cell ± SD are plotted. Comparing PLA signals between VEGF treated 
and non-treated showed significant difference for WT and control conditions; **P ≤ 0.001.
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1M, pyruvate Nas, and glutamine (Invitrogen). Human 
breast carcinoma MDA-MB-231 cells were maintained 
in Dulbecco’s modified Eagle’s medium (DMEM) 
(Gibco, Invitogen) with 10% FBS (Invitrogen) and 2ml 
glutamine (Invitrogen). Melanoma BLM cells (American 
Type Culture Collection (ATCC Manassas, VA)) were 
maintained in DMEM containing 4.5 g/l glucose, 10% 
FBS, 100 U/ml penicillin and 100 mg/ml streptomycin. 
HEK293T cells (ATCC) were cultured in DMEM 
medium (Gibco, Invitogen) supplemented with 10% FBS 
(Invitrogen), 100 U/ml penicillin, 100 mg/ml streptomycin 
and 2ml glutamine (Invitrogen).
Immunoprecipitation and western blotting 
analyses
Cells treated or not with human recombinant VEGF 
(50 ng/ml; R&D Systems) for 5 minutes at 37°C were 
harvested, washed with PBS and lysed in extraction buffer 
(TBS-Nonidet P-40 solution comprising 50mM Tris buffer 
pH 7.5, 150mM NaCl, 0.5% Nonidet P-40, 5mM NaF and 
0.2mM Na3VO4 in the presence of Complete Protease 
Inhibitor Cocktail (Roche)). For immunoprecipitation, 
cell lysates were incubated with antibodies against 
targeted proteins and Protein G-sepharose beads (Sigma). 
Immunoprecipitated proteins were subjected to sodium 
dodecyl sulphate-polyacrylamide gel electrophoresis then 
transferred to Nitrocellulose membranes and probed with 
anti-EMMPRIN mAb (555961, BD-Pharmingen), anti-
VEGF (C-1) mAb (Sc-7269, Santa Cruz), anti-VEGFR-2 
rabbit pAb (Sc-504, Santa Cruz-) or anti-pVEGFR-2 (Tyr 
1175) rabbit mAb (2478, Cell Signaling). The proteins 
were visualized with ECL reagent (Pierce), and their 
expression was normalized relative to total cell lysate 
protein concentration.
In situ proximity ligation assay (PLA)
In situ PLA was used to assess protein-protein close 
proximity. Cells grown on 8-well culture slides (Lab-
tek chamber slides (Nunc, #154534)), were immediately 
fixed and subjected to in situ PLA using the Duolink 
Detection kit (Olink Bioscience, Sweden) according to 
the manufacturer’s instructions. Briefly, after blocking 
slides were incubated with mouse anti-EMMPRIN (1:250, 
555961, BD, Pharmingen), rabbit anti-VEGFR-2 (1:50; 
Santa cruz), mouse anti-VEGF (1:200; Santa cruz) or rabbit 
anti-pVEGFR-2 (Tyr 1175) (1:100; Cell Signalling) primary 
antibodies. PLA minus and PLA plus probes (containing 
the secondary antibodies conjugated with oligonucleotides) 
were added. For VEGFR-2 homodimers detection, primary 
antibody was prepared using the Probemaker kit (OLINK, 
Bioscience) according to manufacturer's instructions: 1 
mg/ml of monoclonal antibody (affinity purified through 
Figure 11: Models of EMMPRIN/VEGFR-2 interaction. (A) Model of the interaction of EMMPRIN (blue) and VEGFR-2 (green) 
on the membrane, based on our EMMPRIN/VEGFR-2 D6-D7 docking models, EMMPRIN dimer docking model, and inter-domain NMA-
based conformational search. With a small rearrangement of VEGFR-2 D7 domains, this model is compatible with D7/D7 dimer x-ray 
structure. (B) Proposed models for the role of EMMPRIN in VEGF-mediated VEGFR-2 activation. (a) According to EMMPRIN/VEGFR-2 
model, EMMPRIN could recruit VEGFR-2 dimers on the membrane surface, which can facilitate binding of VEGF (red) to two VEGFR-2 
monomers and hence favour D7/D7 orientation suitable for activation of VEGFR-2 intracellular domains (activation of intracellular signal 
is represented by a green flash). (b) In the absence of EMMPRIN, VEGFR-2 monomers would be more spread on the membrane surface, so 
VEGF binding to two VEGFR-2 monomers (second step, marked by a dashed arrow) is less likely and therefore activation of intracellular 
signal would be smaller.
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a protein G column) was independently conjugated to each 
of a pair of oligonucleotides to generate plus and minus 
PLA probes. Thereafter, further oligonucleotides are added, 
allowed to hybridize to the PLA probes, and ligase joins 
the two hybridized oligonucleotides to a closed circle. The 
DNA is then amplified (rolling circle amplification), and 
detection of the amplicons was carried by a fluorescently 
labeled probe (Detection Kit 563). Protein complexes 
were visualized in a laser-scanning confocal microscope 
(Leica-Lasertechnik) as bright fluorescent signals. For PLA 
analysis of frozen tumor tissues, cryosections were fixed 
with 4% Paraformaldehyde for 15 min, and in situ PLA 
assay was performed as described above for cultured cells. 
Fluorescent and phase contrast images were taken. Negative 
controls without primary antibody were performed.
Small interfering RNA transfection
siRNA for EMMPRIN (IDs: 147251 (5′ GCCA-
AUGCUGUCUGGUUGCtt 3′) and 215973 (5′ GCU-
ACACAUUGAGAACCUUGtt 3′)) or scrambled siRNA 
oligos (Ambion/Applied-Biosystems, France) were 
transfected into cells by using the Lipofectamine-2000 
(Invitrogen). Cells were then incubated for 24h prior to 
treatment with VEGF and were then analyzed by Co-
immunoprecipitation, Western Blotting, in situ PLA, cell 
migration and phospho-kinase array.
EMMPRIN stable knockdown
In order to knockdown EMMPRIN expression 
in BLM cell line, lentivirus-based miRNA was used. 
MicroRNA sequence EMMPRIN-miRNA (5′- TTCATGAG-
GGCCTTGTCCTCA-3′) targeting human EMMPRIN was 
selected with Invitrogen Block-iTRNAi Designer software 
(http://www.invitrogen.com/rnai), and srambled-miRNA 
(Invitrogen) was used for the negative control [20].The U6 
promoter-miRNA-Ubiquitin promoter-mCherry cassette 
was cloned into the BamHI and XhoI sites in the lentiviral 
vector pTK431 [24]. The vector plasmids (either pTK431-
EMMPRIN-miRNA or pTK431-scrambled-miRNA), 
together with the packaging construct plasmid pDNRF and 
the envelope plasmid pMDG-VSVG, were cotransfected into 
HEK293T cells to produce the viral particles [24, 25]. The 
viral titres were determined by p24 antigen measurements 
(KPL, Lausanne, Switzerland). BLM cells were plated in 
a 24-well plate at a density of 10.000 cells/well in culture 
medium. At 60% of confluent, LV-EMMPRIN-miRNA 
(121 ng/μL of P24) or LV-scrambled-miRNA (97 ng/μL 
of P24) was added in 100 μl of complete culture medium 
without FBS. After overnight incubation with the vectors, 
medium was refreshed and cells were allowed to growth. 
For determination of transduction efficiencies, transduced 
cultures were analyzed by cell sorting with a FACS ARIAIII 
(Becton-Dickinson, San Jose, CA, USA), real-time PCR, 
Western blotting and invasion assay.
Real-time quantitative PCR (qRT-PCR)
Total RNA was extracted from BLM-scrambled-
miRNA or BLM-EMMPRIN-miRNAcells using Trizol 
reagent (Invitrogen). RNA quantity and quality were assessed 
using the Nanodrop-ND-1000 (Nanodrop Technologies, 
Wilmington). First-strand cDNA was synthesized using a 
High-Capacity cDNA Archive Kit (Applied-Biosystems) 
according to the manufacturer’s protocol. EMMPRIN 
primers were specifically designed (Eurogentec, Belgium). 
Transcript levels were measured by qRT-PCR using Perfect 
Master Mix-Probe (AnyGenes, France) on LightCycler-480 
(Roche) according to the manufacturer’s protocol. The 
transcript levels were normalized to the housekeeping PPIA 
(peptidylprolylisomerase A) transcripts.
Immunofluorescence, confocal microscopy
Sections of BLM-Scrambled-miRNA and BLM-
EMMPRIN-miRNA derived tumor tissues were fixed and 
incubated with primary anti-pVEGFR-2 antibody (Cell 
signaling) followed by Alexa Fluor 488 fluorescently 
conjugated secondary antibody (Molecular Probes). DAPI 
was used for nuclear counterstaining. Confocal images 
were taken with a Leica inverted confocal microscope 
(Leica Lasertechnik, Heidelberg).
Animal experiment
Mouse experiments were conducted according 
to French veterinary guidelines and those formulated 
by the council of Europe for experimental animal use 
(L358–86/609EEC). Female 5-week-old nude/c mice 
(Janvier) were injected subcutaneously with 5 × 106 stably 
transfected BLM-EMMPRIN-miRNA or BLM-scrambled-
miRNA cells (n = 10 mice for each cell line). Five weeks 
later, all mice were sacrificed by cervical dislocation and 
tumors were resected and stored in liquid nitrogen prior to 
in situ PLA and immunofluorescence assays.
Migration and invasion assays
The in vitro migration (on uncoated filters) and 
invasion (on coated filters with matrigel, BD Bioscience) 
were performed using a modified Boyden chamber [26] in 
24-well plates and 8-mm pore filter inserts (BD Bioscience). 
After 24h of incubation, cells were fixed, stained with 
crystal violet 0.5% and counted under a light microscope.
Human phospho-kinase array
The human phospho-Kinase Array Kit (Proteome 
Profiler Array, ARY003, R&D Systems) was used to 
detect relative levels of phosphorylation of 46 kinase 
phosphorylation sites, according to the manufacturer’s 
instructions, using total cell lysates of EMMPRIN or 
scrambled siRNA transfected HMEC cells treated or not 
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with 50 ng/ml VEGF. Briefly, cell lysates diluted to 300 
μg/mL of protein in a detergent- urea and phosphatase 
inhibitor-containing solubilizing buffer (R&D Systems) 
were incubated with the arrays overnight at 4°C. After 
washing unbound material, membranes were incubated 
with a cocktail of phosphosite–specific, biotinylated 
antibodies, and phosphorylated kinases were detected 
with streptavidin-horseradish peroxidase. Signals were 
revealed with a chemiluminescent substrate kit (ECL Dura 
Thermo Scientific, 34076). Independent experiments were 
performed in duplicates.
Modelling: general consideration
We modelled EMMPRIN/VEGFR-2 association by 
using homology-based modeling, computational docking, 
and conformational sampling by normal mode analysis 
(NMA) (Figure 10). On the one side, we built a model for 
VEGFR-2 D6-D7, and we docked it to EMMPRIN x-ray 
structure. The EMMPRIN/VEGFR-2 docking model was 
later confirmed by site-directed mutagenesis. We also used 
docking to build models for EMMPRIN dimerization. 
The docking models obtained for EMMPRIN/VEGFR-2 
and EMMPRIN dimer, in combination with NMA-based 
sampling, were compatible with membrane attachment, 
and with D7 x-ray dimers. We tried other docking 
combinations but could not find any better model.
Homology-based modeling of VEGFR-2 D6-D7
We used Modeller 8v1 [27] to model the structure 
of VEGFR-2 D6-D7 domains from 1F97 PDB template 
structure, with 24% of sequence identity and selected by 
FUGUE server (http://tardis.nibio.go.jp/fugue/prfsearch.
html) [28] as the best homologous topology. The D7 
coordinates in the model were replaced by the known 
x-ray structure (3KVQ PDB). The resulting D6-D7 
construct (in particular the linker between D6 and D7 
domains) was finally refined by Modeller 8v1.
Computational docking
Computational docking was performed by 
combining the 10,000 output solutions from FTDock 2.0 
[29] and the 2,000 ones from ZDock 2.1 [30]. The resulting 
12,000 solutions were then scored by pyDock [31].
Energetic analysis of interaction model
The best docking model for EMMPRIN D1-D2/
VEGFR-2 D6-D7 was energetically minimized using 
Tinker (http://dasher.wustl.edu/tinker/). The global binding 
energy had a clear electrostatic contribution. The binding 
energy per residue was calculated for this minimized 
structure using pyDock [31]. Residues with the highest 
electrostatic contribution were further considered for 
selecting mutant candidates (Figure 7B).
NMA-based conformational sampling
We used iMC module from iMOD [32] (with a 
maximum amplitude of 6Å) for conformational sampling 
of extracellular EMMPRIN and VEGFR-2 D6-D7 model. 
With this method, we generated 100 conformations 
independently for EMMPRIN and VEGFR-2 D6-D7 
monomers. These NMA-based EMMPRIN conformations 
were combined to produced new EMMPRIN dimer 
models, built based on the main dimer interface described 
by the EMMPRIN/EMMPRIN docking model. These 
EMMPRIN dimer models were combined with the NMA-
based VEGFR-2 D6-D7 conformations, based on the 
main interface described by the EMMPRIN/VEGFR-2 
D6-D7 docking model. This generated 10,000 (2:2) 
EMMPRIN/VEGFR-2 D6-D7 models. Finally, when 
considering cell membrane, we obtained a total of 32 
models in which C-term regions from all molecules were 
located approximately in the same plane (to represent the 
attachment to the membrane) and with more than 80% 
of the atoms located in one side of the defined plane 
(in order to disregard strong steric clashes with the cell 
membrane).
Site directed mutagenesis
EMMPRIN residues (Asp144, Gln182, Arg184, 
Gln195, Asp136 and Thr199) involved in the interaction 
between EMMPRIN and VEGFR-2 were mutated to Ala-
nine using « Geneart Site-Direct Mutagenesis system » 
(Lifetechnologies) according to the manufacturer’s 
instructions. The following mutations were made in the 
PCRII vector containing EMMPRIN full length cDNA 
(PCRII-EMMPRIN) [10]. Briefly, the mutagenesis 
reactions were performed using Platinum Taq DNA 
polymerase (Lifetechnologies), with specifically designed 
mutagenesis primers (Table 1) and cycling conditions as 
follows: 37°C for 20 minutes, 94°C for 2 minutes followed 
by 18 cycles of 94°C for 20 seconds, 57°C for 30 seconds 
and 68°C for 2.5 minutes; and finally 1 cycle of 68°C for 
5 minutes. Each mutagenesis product was transfected into 
chemically competent DH5α T1R E.coli (Lifetechnologies) 
and grown at 37°C overnight. Colonies were selected and 
screened for the correspondant mutation at each site by 
DNA sequencing. PCRII-EMMPRIN wide type (WT) and 
mutated were transfected into BLM-EMMPRIN-miRNA 
cells using the Lipofectamine-2000 (Invitrogen).
Statistical analysis
Data are presented as the mean values ± SD. Mann-
Whitney test was used to evaluate differences between 
groups. Data were considered statistically significantly 
different for P value < 0.05. All statistical tests were two-
sided. Analyses were performed using Prism 6 (GraphPad 
Software Inc, La Jolla, CA).
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